Asthma Clinical Trial
Official title:
Asthma and Mindfulness-Based Stress Reduction (MBSR)
Asthma is one of the four most common chronic disorders in adults, affecting 14 million adults in the United States and costing an estimated 7.9 billion dollars in medical care and 5.3 billion dollars in lost work or school. About 40% of asthmatics report using some form of complementary and alternative medicine approach to help reduce their asthma symptoms, but there is little evidence for their effectiveness. Mindfulness-based stress reduction (MBSR) is a group based program shown to reduce medical symptoms and improve quality of life for patients with many different chronic diseases. The goals of the proposed randomized controlled trial are to collect preliminary data on the effect of MBSR on quality of life, symptoms, and lung function in mild and moderate-severity asthmatics and to refine recruitment and data collection procedures for a future, larger clinical trial.
Asthma is a chronic respiratory disease that affects 7% or 14 million adults in the United
States. It is one of the four most common chronic disorders in adults, costing an estimated
7.9 billion dollars in medical care and 5.3 billion dollars in lost work or school.
Approximately 40% of asthmatics report using some form of complementary and alternative
medicine (CAM) approach to help alleviate their asthma symptoms, but there is little
evidence for their effectiveness. Breathing and relaxation techniques, including yoga appear
most promising. Mindfulness-based stress reduction (MBSR) is a group-based program developed
at the University of Massachusetts Medical School (UMMS) that focuses on the cultivation of
mindfulness through formal meditation practices and the integration of mindfulness into
everyday life as a coping resource to deal with physical symptoms, chronic medical
conditions, and difficult emotional situations. MBSR has been shown to be an effective
adjunctive intervention in reducing medical symptoms for a broad range of stress-related
disorders and chronic diseases, reducing psychological distress anxiety and depression, and
improving quality of life. A small preliminary study conducted by our research team found
improvements in measures of quality of life, locus of control, stress, and anxiety
immediately following the completion of the MBSR program.
The overall goal of the proposed two year exploratory study is to conduct a randomized
controlled trial (RCT) to test and optimize recruitment and data collection procedures and
to collect preliminary data on the effect of MBSR on behavioral and psychological aspects of
asthma and lung function to support justification for a larger clinical trial should the
results of this study be promising. Eighty-two adults ages 21 and older with a
physician-documented diagnosis of asthma classified as either mild or moderate documented
will be recruited for seventy participants at final follow-up. Participants will be randomly
assigned to one of two conditions stratified by asthma severity: (1) MBSR, or (2) Healthy
Living Course (HLC) attention control condition. Participant assessments will occur at study
entry (baseline) and at 10-week, 6- and 12-month follow-up. The primary aim of the project
is to evaluate the efficacy of the MBSR program in improving quality of life and lung
function as assessed by change from baseline to two-week average morning peak expiratory
flow (PEF) compared to HLC participants. Secondary aims are to evaluate the effect of the
MBSR program on reducing asthma rescue medication use, frequency of asthma exacerbations
(prednisone therapy), asthma symptoms, healthcare utilization, number of days of work or
school missed, peak expiratory flow (PEF) variation, and psychological distress, and in
improving asthma control, asthma-related internal locus of control, and lung function as
assessed by spirometry (FEV1).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|